8-K: Theravance Biopharma Reports Mixed Q2 Results, YUPELRI Sales Dip Slightly, CYPRESS Trial Delayed

Theravance Biopharma's second quarter results show a slight decrease in YUPELRI sales, but strong growth in hospital demand, while the CYPRESS trial for ampreloxetine is experiencing enrollment delays.

Summary

• Theravance Biopharma reported a 1% decrease in YUPELRI net sales to $54.5 million in Q2 2024 compared to Q2 2023, attributed to changes in channel mix and lower net prices.
• Despite the sales dip, customer demand for YUPELRI increased by 13% year-over-year, and hospital doses sold rose by 43%.
• The company's collaboration revenue with Viatris was $14.3 million, a 4% increase from the same quarter last year.
• The CYPRESS trial for ampreloxetine is now expected to complete enrollment in mid-2025, with top-line data anticipated approximately six months later, due to longer site activation timelines.
• TRELEGY net sales reached $1.065 billion in Q2 2024, increasing the likelihood of Theravance achieving up to $50 million in milestone payments this year.
• Theravance's cash balance at the end of Q2 2024 was $96.1 million.
• The company incurred a $3.0 million non-cash impairment charge on long-lived assets due to a softening R&D lab space leasing market.
• Non-GAAP net loss from operations was $6.3 million for the quarter, compared to $7.4 million in the same period last year.
• The company is exploring opportunities to unlock value from its Irish tax assets.
• Patent litigation with four companies regarding generic versions of YUPELRI has been settled, granting licenses for launch after April 2039.
• An additional method of use patent for YUPELRI was granted on July 30, 2024, expiring in August 2039.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positives like strong demand for YUPELRI and TRELEGY's performance, the sales decrease for YUPELRI and the delay in the CYPRESS trial temper the overall outlook. The non-cash impairment charge also adds a negative element.

Positives

• Customer demand for YUPELRI increased by 13% year-over-year, indicating strong underlying product interest.
• Hospital sales of YUPELRI grew significantly, with a 43% increase in doses sold compared to the same quarter last year.
• YUPELRI achieved record market share in both hospital and community settings, surpassing 18% and 32% respectively.
• Viatris' submission of the YUPELRI NDA in China presents a significant growth opportunity, with a potential $7.5 million milestone payment.
• TRELEGY's strong sales performance increases the likelihood of Theravance receiving up to $50 million in milestone payments in 2024.
• The company has settled patent litigation related to YUPELRI, securing market exclusivity until 2039.
• An additional method of use patent for YUPELRI was granted, extending IP protection to August 2039.

Negatives

• YUPELRI net sales decreased by 1% year-over-year, indicating some challenges in the commercialization of the product.
• The CYPRESS trial for ampreloxetine has been delayed, with the last patient enrollment now expected in mid-2025.
• The company incurred a $3.0 million non-cash impairment charge on long-lived assets, reflecting a softening R&D lab space leasing market.
• The company reported a net loss of $16.5 million for the quarter, although non-GAAP net loss was lower at $6.3 million.

Risks

• The delay in the CYPRESS trial could impact the timeline for ampreloxetine's potential approval and commercialization.
• The decrease in YUPELRI net sales, despite strong demand, suggests potential pricing or channel mix issues that need to be addressed.
• The non-cash impairment charge indicates potential challenges in the company's real estate holdings.
• The company's future profitability is subject to various risks, including clinical trial outcomes, regulatory approvals, and market conditions.
• The company is dependent on third parties for the commercialization of YUPELRI and TRELEGY, which introduces risks related to their performance.

Future Outlook

The company expects levels of both non-GAAP losses and cash burn to be similar to the first half of 2024. They are also exploring opportunities to unlock value from their Irish tax assets and are focused on growing YUPELRI sales, advancing ampreloxetine, and optimizing financial returns.

Management Comments

• Rick Winningham, Theravance Biopharma CEO, stated that YUPELRI net sales decreased due to near-term headwinds from an evolved channel mix and a lower realized net price.
• Mr. Winningham expressed disappointment with the YUPELRI sales result but remains confident in the product's future growth.
• Mr. Winningham noted that the CYPRESS trial enrollment is now expected to complete in mid-2025.
• Mr. Winningham expressed pleasure with TRELEGY's performance, increasing confidence in achieving milestones in 2024.

Industry Context

The report highlights the competitive landscape in the COPD treatment market, with YUPELRI facing challenges in net sales despite strong demand. The delay in the CYPRESS trial also underscores the complexities of drug development in the neurodegenerative space. The strong performance of TRELEGY, a triple therapy for COPD, reflects the ongoing demand for effective treatments in this area.

Comparison to Industry Standards

• YUPELRI's 1% sales decrease contrasts with the 40% growth in TRELEGY sales, indicating a potential shift in market preference towards triple therapies or challenges in YUPELRI's commercial strategy.
• The 13% increase in customer demand for YUPELRI, despite the sales decrease, suggests a potential pricing or channel mix issue, which could be compared to other companies facing similar challenges in the pharmaceutical market.
• The delay in the CYPRESS trial is not uncommon in clinical development, but it highlights the challenges in enrolling patients for rare diseases like MSA, which can be compared to other companies' experiences in similar trials.
• The non-cash impairment charge of $3.0 million due to a softening R&D lab space leasing market is a common issue in the biotech industry, especially in areas with high concentrations of biotech companies like South San Francisco.
• The company's focus on maximizing shareholder value through tax asset exploration is a strategy employed by other companies with international operations and complex tax structures.

Stakeholder Impact

• Shareholders may be concerned about the decrease in YUPELRI sales and the delay in the CYPRESS trial, but encouraged by the potential for TRELEGY milestone payments and the exploration of tax asset value.
• Employees may be affected by the company's financial performance and strategic decisions.
• Patients with COPD may benefit from the continued availability of YUPELRI, while those with MSA are awaiting the results of the CYPRESS trial for ampreloxetine.
• Viatris, as a partner, is impacted by the performance of YUPELRI and the progress of the China NDA.
• Royalty Pharma, as a partner, is impacted by the sales of TRELEGY and the associated milestone payments.

Next Steps

• The company will continue to focus on growing YUPELRI sales in the US and expanding into China.
• They will continue to enroll patients in the CYPRESS trial and expect top-line data approximately six months after the last patient enters the open-label portion of the study.
• The company will explore opportunities to unlock value from its Irish tax assets.
• They will monitor TRELEGY sales to achieve potential milestone payments.

Key Dates

Keywords

YUPELRI, Ampreloxetine, TRELEGY, COPD, MSA, nOH, Clinical Trial, Milestone Payments, Patent, Viatris, Royalty Pharma, Financial Results